EUVIMEDEUVIMED entdecken
Crossref

Clinical pharmacological innovation in the treatment of depression

Jeffrey M Witkin, Lalit K Golani, Jodi L Smith iD

Expert Review of Clinical Pharmacology · 2023

DOI: 10.1080/17512433.2023.2198703 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Expert Review of Clinical Pharmacology, 2023. Verfasst von Jeffrey M Witkin und 2 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Antiepileptic Drug Discovery, Ascension St. Vincent Hospital, Indianapolis, IN, USA. Hauptthemen laut MEDLINE: Major Depressive Disorder, Hallucinogens, Ketamine. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 144 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Deficiencies in standard of care antidepressants are driving novel drug discovery. A new age of antidepressant medications has emerged with the introduction of rapid-acting antidepressants with efficacy in treatment-resistant patients. AREAS COVERED: The newly approved medicines and those in clinical development for major depressive disorder (MDD) are documented in this scoping review of newly approved and emerging antidepressants. Compounds are evaluated for clinical efficacy, tolerability, and safety and compared to those of standard of care medicines. EXPERT OPINION: A new age of antidepressant discovery relies heavily on glutamatergic mechanisms. New medicines based upon the model of ketamine have been delivered and are in clinical development. Rapid onset and the ability to impact treatment-resistant depression, raises the question of the best first-line medicines for patients. Drugs with improvements in tolerability are being investigated (e.g. mGlu2/3 receptor antagonists, AMPA receptor potentiators, and novel NMDA receptor modulators). Multiple companies are working toward the identification of novel psychedelic drugs where the requirement for psychedelic activity is not fully known. Gaps still exist - methods for matching patients with specific medicines are needed, and medicines for the prevention of MDD and its disease progression need research attention.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Major Depressive DisorderHallucinogensKetamineHumansDepressionAntidepressive Agents

Stichwörter der Autor:innen

AntidepressantNMDA receptorsketaminemajor depressive disorderpsychedelicstreatment-resistant depression

Substanzen

HallucinogensAntidepressive AgentsKetamine

Autor:innen und Institutionen

  • Laboratory of Antiepileptic Drug Discovery, Ascension St. Vincent Hospital, Indianapolis, IN, USA.
  • Departments of Neuroscience and Trauma Research, Ascension St. Vincent Hospital, Indianapolis, IN, USA.
  • Department of Chemistry and Chemical Biology, Northeastern University, Boston, MA, USA.

ORCID-Profile: Jodi L Smith

Zitieren

APA

Witkin, J. M., Golani, L. K., & Smith, J. L. (2023). Clinical pharmacological innovation in the treatment of depression. Expert Review of Clinical Pharmacology. https://doi.org/10.1080/17512433.2023.2198703

Vancouver

Witkin JM, Golani LK, Smith JL. Clinical pharmacological innovation in the treatment of depression. Expert Review of Clinical Pharmacology. 2023. doi:10.1080/17512433.2023.2198703

BibTeX
@article{Witkin2023,
  author = {Witkin, Jeffrey M and Golani, Lalit K and Smith, Jodi L},
  title = {Clinical pharmacological innovation in the treatment of depression},
  journal = {Expert Review of Clinical Pharmacology},
  year = {2023},
  doi = {10.1080/17512433.2023.2198703}
}
Kostenlos starten →